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To test the hypothesis that cellular proteinases contrib-
ute to ischemic myocellular death, measurements were
made of tyrosine release (an index of overall proteolysis)
from incubated slices of nonischemic and ischemic myo-
cardium obtained at various times after coronary artery
occlusion in rats. Proteolysis failed to increase in isch-
emic myocardium throughout the first 24 hours of oc-
clusion, when irreversible damage develops, indicating
that cellular proteinases do not undergo generalized ac-
tivation in this phase. These data represent the first as-
sessment of myocardial proteolysis throughout the de-
velopment of ischemic death, and suggest that cellular
proteinases do not play a causal role in this process.
However, the possibility remains that ischemia selec-
tively accelerates the breakdown of vital proteins, a phe-
nomenon that may not be detected by measuring overall
proteolysis. To determine whether future studies on the
effects of proteolytic inhibition on infarct size are fea-
sible, the ability of the proteinase inhibitors antipain,
leupeptin, pepstatin and chymostatin, given in vivo, to
interfere with proteolysis in ischemic myocardium was
In recent years, considerable interest has focused on the
possible role of lysosomal enzymes in the production of
irreversible damage during acute myocardial infarction, Ly-
sosomal enzymes undergo a subcellular redistribution and
a shift from the particle-bound to the nonsedimentable frac-
tion of tissue homogenates 0-10), Biochemical, immu-
nohistochemical and ultrastructural studies have demon-
strated that cathepsin D, a major lysosomal protease, is
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also evaluated. Leupeptin (10 or 40 mg/kg) inhibited
proteolysis in a dose-related fashion ( - 49 and -72%,
respectively, p < 0.001). Antipain (20 mg/kg) decreased
protein breakdown by 60% (p < 0.001). The combi-
nation of antipain (20 mg/kg), leupeptin (40 mg/kg) and
pepstatin (5 mg/kg) suppressed proteolysis almost com-
pletely at both 15 minutes (- 88%, P < 0.001) and at 6
hours ( -72%, p < 0.05) of ischemia, that is, throughout
the development of irreversible injury.
These results demonstrate that whatever proteolysis
is occurring during acute myocardial infarction is largely
mediated by cathepsins A, B, D, Land H and by calcium-
activated neutral protease (that is, the enzymes sensitive
to the inhibitors used). Because antipain, leupeptin and
pepstatin significantly suppress such proteolysis, these
agents might be useful in further assessing any potential
contribution of cellular proteinases to the production of
ischemic myocellular death. In addition, this study pro-
vides a new experimental model that affords serial as-
sessments of regional myocardial proteolysis during the
evolution of myocardial infarction.
released from the lysosome and widely dispersed within the
cytoplasm as early as 30 minutes after coronary artery oc-
clusion 01-13), before the appearance of electron micro-
scopic evidence of irreversible damage (9), These obser-
vations have led to the hypothesis that lysosomal proteinases
contribute to irreversible damage by digesting vital cellular
constituentsearly in the course of myocardial ischemia (11,14-
16), as well as by leaking out of injured cells to attack
adjacent, still viable myocytes (4).
This hypothesis is not supported by the finding that over-
all proteolysis decreases in isolated Krebs-Henseleit-per-
fused rat hearts during a short period (60 minutes) of flow
reduction 07,18). However, data on proteolysis in the set-
ting of regional acute myocardial ischemia produced in the
in situ blood-perfused heart are lacking. Moreover, histo-
chemical studies (9) suggest that in the rat model, my-
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ocellular damage in vivo progresses after the 60 minute
period of ischemia explored in the previously cited exper-
iments.Therefore, in the present investigation, we measured
tyrosine production, an index of overall proteolysis (20), in
nonischemic and ischemic myocardium of in situ blood-
perfused rat hearts. These measurements were obtained se-
rially Over the entire first 24 hours of myocardial ischemia,
during which time irreversible myocellular damage should
have been completed.
The significance of proteolysis in ischemic myocardium
might be further clarified by suppressing such activity in
vivo and by evaluating the effect of this suppression on the
magnitude of ischemic cell necrosis. Therefore, a second
purpose of this investigation was to determine whether pro-
teolysis could be inhibited by in vivo administration of sev-
eral potent proteinaseinhibitorsrecentlydevelopedby Ume-
zawaet aI. (21): leupeptin, an inhibitor oflysosomal cathepsins
B, L, H (21) and of cytoplasmic calcium-activated neutral
protease (22); antipain, an inhibitor of cathepsins A and B
(21) and of calcium-activated neutral protease (22); pepsta-
tin, an inhibitor of cathepsin D (21); and chymostatin, an
inhibitor of cathepsins Band G (21). It was our plan to
carry out a subsequent study on the effects of proteolytic
inhibition on infarct size, if inhibition could be achieved.
Methods
Experimental preparation. Male Sprague-Dawley rats
(230 to 270 g) were anesthetized withether. A thoracotomy
was performed in the left fifth intercostal space and the left
coronary artery was ligated 2 to 4 mm below the level of
the pulmonary valve as described previously (19). Fifteen
minutes or I, 2, 6, 18 or 24 hours after occlusion, the rats
were stunned by a blow to the head and the heart was rapidly
excised. In those that were killed at 15 minutes, 2 and 6
hours, I ml of black ink was injected intravenously im-
mediately before sacrifice to delineate the ischemic region
of the left ventricle (Fig. I). No staining was necessary in
rats killed 18 or 24 hours after occlusion because the infarct
wasevident at inspection as a thin, discoloredanddyskinetic
zone.
Quantification of proteolysis in nonischemic and isch-
emic ventricular myocardium. The ischemic region was
rapidly excised from the rest of the heart, and the ischemic
and nonischemic portions were immediately immersed in
ice-cold "ischemic" or "aerobic" medium, respectively .
The "aerobic" medium was a Krebs-Ringer bicarbonate
buffer (23) equilibrated with a mixture of. 95% oxygen (02)
and 5% carbon dioxide (C02) , pH 7.4, and supplemented
with 10 roM glucose, 0.1 Uzrnl of insulin (Sigma Chem-
ical Co.), 100 U/ml of penicillin and 100 J,LIml of strepto-
mycin (Grand Island Biological Co.). This medium resem-
bles the extracellular fluid in normallyperfusedtissues (24).
The " ischemic" medium differed from the aerobic in that
it had a lower bicarbonatecontent (13 versus 27 mliq/liter) ,
it was saturated with a mixture of 90% nitrogen (N2) and
10% COz and, therefore, had a lower pH (6.8); furthermore,
the solution lacked glucose and insulin. This medium re-
sembles the extracellular fluid of ischemic tissues, in which
the pressure of carbon dioxide (Pco-) increases, pH de-
creases to approximately 6.8 (25) and nutrients and hor-
mones are lacking.
Subepicardial slices with an average weight of 70 mg
wererapidlyobtained fromnonischemicand ischemic tissue
using a chilled Stadie-Riggs microtome. Slices were gently
blotted, divided into halves and weighed. One half of each
slice was immediately homogenized in either the aerobic or
ischemic medium (as described later) to determine tyrosine
concentration. This value was assumed to represent the ty-
rosine concentration in the incubatedtissue at the beginning
of incubation. The other half of the slice was placed in a
25 ml sterile Erlenmeyerflask containing 3.0 ml of aerobic
or ischemic medium. Both incubation media were supple-
mentedwithcycloheximide, 0.5 roM (SigmaChemicalCo.);
this concentration has been shown to inhibit cardiac protein
synthesis by more than 95% (20). The atmosphere above
the aerobic or ischemic medium was equilibrated with 95%
Oz and 5% COz or 90% Nz and 10% CO2 , respectively, by
gassing flasks with the appropriate gas mixture for 10 min-
utes. Slices were incubated for] hour at 37°C with contin-
uous gentle shaking (approximately 80 cycles/min). Unless
otherwise specified, nonischemic and ischemic tissues were
incubated with aerobic and ischemic medium, respectively.
Determination of tyrosine release. At the end of the in-
cubation period, each slice was removed from its medium.
Proteinwas removedfrom a 2.0 ml sample of the incubation
medium by trichloroacetic acid precipitation (final concen-
tration, 10%) and centrifugation at 2,500 g for 30 minutes;
a 2.0 ml aliquot of the supernatantwas assayed for tyrosine
(26) to determine the amount of tyrosine released into the
medium during incubation . Each slice was blotted and im-
mediately homogenized in 1.0 ml of fresh incubation me-
dium; the homogenizing tubes wererinsedwithan additional
1.0 ml of medium. Homogenate and wash were combined
with0.5 ml of ice-cold50% trichloroacetic acid, mixed and
centrifuged at 2,500 g for 30 minutes. A 2.0 ml aliquot of
supernatant was removed and assayed for tyrosine to de-
termine slice concentration of tyrosine at the end of incu-
bation. In 789 samples, the protein pellets of both homog-
enate and medium were dissolved in 2.0 ml of I M sodium
hydroxide . An aliquot of this solution was assayed for pro-
teins by the method of Lowry et al. (27).
Tyrosine release was calculated by adding the amount
released into the medium during incubation to the amount
present in the slice at the end of incubation and then sub-
tracting the tyrosine content of the slice at the beginning of
incubation. Tyrosinereleasewas relatedto tissue wet weight
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Figure 1. A typical example of demarcation of ischemic region
by intravenous injection of black ink. The ischemic region is ev-
ident as a large unstained area (white) occupying most of the left
ventricular free wall and clearly separated from the normally per-
fused myocardium (black). The arrow indicates the coronary
ligature.
in all experiments and, in most experiments, also to the
amount of protein available for breakdown in the slice;
results obtained with the two method s were similar. Protein
available for breakdown in the slice was computed as fol-
lows: the protein concentration in the homogenized half of
each original slice was assumed to also represent the con-
centration in the incubated half at the beginning of incu-
bation . This value was mult iplied by the wet weight of the
incubated tissue to give total protein content at the start of
incubation. By subtracting from this quant ity the amount of
protein leaked into the medium during incubation (deter-
mined on the trichloroacetic acid precipitate from the me-
dium sample) , the total amount of protein available for
degradation in the slice was calculated.
Linearity of tyrosin e release during 1 hour of incubation
was assessed in different tissues: nonischemic ventricular
myocardium of rats not under going coronary occlu sion and
15 minute and 6 hour ischemi c ventricular myocardium.
Slices of each tissue were incubated for 20, 40 or 60 min-
utes, and tyrosine releas e was measured as described.
Evaluation of the effects of antipain, leupeptin, pep-
statin and chymostatin on proteolysis in nonischemic and
ischemic ventricular myocardium. Multiple experiments
were conducted to assess the effects of proteinase inhibitors ,
admini stered in vivo separately or in combination, on myo-
cardial proteol ysis. The detail s of these experiments are
specified in Table I. The water-soluble agents, antipain and
leupeptin , were dissolved in normal saline solution, whereas
pepstatin and chymostatin , which are minimally soluble in
water, were dissolved in dimethylsulfoxide. In Groups I to
12, in which coronary artery occlusion was performed, pro-
teolysis was measured in both ischemic and nonischemic
myocardium . Determination of proteol ysis was limited to
nonischemic myocardium in Groups 13 to 18, which did
not undergo coronary occlusion.
Proteolysis in atria. Tyrosine release by atrial myo-
cardium was determined in rats used as controls for as-
sessment of ventricular proteolysis (Group 13 ). The right
and left atria were excised and blotted gently. Part of the
atria was homogenized immediately and the remainder was
incubated in aerobic medium . The rest of the experiment
was conducted as described previously.
Proteolysis during the first 24 hours of acute myo-
cardial infarction. To determine the changes in proteolysis
that occur during the development of ischemic necrosis ,
tyrosine release was measured in slices of nonischemic or
ischemic myocardium , or both , obtained from control rats
not subjected to occlu sion (Group 13) and from control rats
at various times after coronary occlusion: 15 minutes (Group
5 ), I hour , 2 hours (Group I), 6 hours (Group 8) and
18 and 24 hours. To assess the effect of the incubation
medium itself on proteol ysis , replic ate slices of nonischemic
and ischemic myocardium were obtained from control rats
killed 2 hours after coronary occlusion (Group 1); one slice
was incubated in aerobic medium and the other in ischemic
medium.
Statistical analysis. All value s are expressed as mean
± standard error of the mean. Differences between two
groups were analyzed by unpaired Student's t test. One way
analysis of variance was used for simultaneous multiple
compari sons; if the F test revealed significant differences
among groups, the level of significance for each comparison
was determined by the Bonferroni method (28) .
Results
The rate of tyrosine release remained approximately con-
stant for I hour (incubation time used in this study) in both
15 minute and 6 hour ischem ic myocardium as well as in
nonischemic myocardium (Fig . 2) . Stability of tyrosine re-
lease by tissue preparations dur ing a I hour incubation af-
forded valid comparisons between control and treated rats.
Changes in myocardial proteolysis after coronary ar-
tery occlusion. Figure 3 illustrates proteolysis in control
rats not subjected to coron ary occl usion and in control rats
sacrificed at various times after occlusion. Although pro-
teolysis in nonischemic myocardium decreased somewhat
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Table 1. Protocols of the Experiments With Proteinase Inhibitors
Interval From
Route of Occlusion to
Administration Sacnfice
iv 2 h
iv 2 h
iv 2 h
iv 2 h
iv 15 min
iv 15 min
Group
{ ~
5
6 '
7
8
9
Treatment
NS. 0.25 milOmin preocclusion
A. 12 mg/kg 20 min plus 8 mglkg 10 min
preocclusion (total: 20 mglkg)
L. 10 mg/kg 10 min preocctusion
L. 40 mg/kg 10 min prcocclusron
NS. 0.3 rnl 45 min plus 0.4 ml 30 min plus
0.2 ml 15 min plus 0.3 ml I min
preocclusion (total: 1.2 ml)
A. 12 mg/kg 45 min plus A. 8 mglkg and L.
20 mg/kg 30 min plus L. 20 mg/kg 15 min
preocclusion (total: A. 20 rng/kg plus L. 40
rng/kg)
A. 12 rng/kg and P. 1.3 mg/kg 45 min plus A.
8 mg/kg and L, 20 mg/kg and P. I. 7 rng/kg
30 min plus L. 20 mg/kg and P, 0.8 mg/kg
15 nun plus P. 1.2 rng/kg I min
preocclusion (total: A. 20 mg/kg plus L, 40
rng/kg plus P, 5 mg/kg)
NS as In Group 5 preocclusion plus 1.2 ml 2 h
postocclusion plus 1.2 ml 4 h postocclusion
A plus L plus P as in Group 7 preocclusion
plus A. 20 mg/kg and L. 40 mg/kg and p. 5
mg/kg 2 h postocclusion plus A. 20 mg/kg
and L. 40 mg/kg and P, 5 mg/kg 4 h
postocclusion
Vehicle
NS. 0.25 ml
NS, 0.25 ml
NS. 0.25 ml
NS as in
Group 5
NS as in
Group 5
NS as in
Group 8
iv
iv preocclusion
ip postocclusion
iv prcocclusion
Ip postocclusion
15 min
6h
6 h
1
10
II
12
(
13
14
15
{
16
17
18
DMSO. I ml 18 h plus I ml I h preocclusion
P. 8 rng/kg 18 h plus 8 mg/kg I h
preocclusion
C. 60 mg/kg 18 h plus 60 mg/kg I h
preocc1usion
NS. 0.4 ml 20 min presacrifice
A, 20 mglkg 20 min presacrifice
L. 40 mg/kg 20 rmn presacrifice
NS. 1.0 ml 18 h plus 1.0 ml I h presacnfice
DMSO. 1.0 ml 18 h plus 1.0 ml I h
presacrifice
P. 8 mg/kg 18 h plus 8 mg/kg I h presacrifice
DMSO. 2 ml
DMSO. 2 ml
NS. 0.25 ml
NS. 0.25 ml
DMSO, 2 ml
ip 3 h
ip 3 h
ip 3 h
iv No occlusion
IV No occlusion
IV No occlusion
ip No occlusion
ip No occlusion
Ip No occlusion
A = antipam: C = chymosrann: DMSO = dimethylsulfoxide: I p. = intraperitoneally: i.v. = intravenously; L = leupeptin; NS = normal saline
soluuon; P = pepstatm, Braces identify different experiments.
after coronary occlusion (poss ibly as a result of surgical
trauma or hemodynamic changes), differences were not sta-
tisticall y significant. Proteolysis in ischemic myocardium
was similar at 15 minutes and at 1 and 2 hours after coronary
occlu sion , but decreased significantly by 6 hours (proba-
bility [p] < 0.01 versus 15 minutes). Proteol ysis then in-
creased , reach ing value s at 18 hours after occlu sion similar
to those observed at 2 hours . At 24 hours after occlu sion,
proteolysis was significantly (p < 0.001 ) greater than at 6
hours, but not statistically different from that measured dur-
ing the first 2 hours. At no time during the first 24 hours
of occlu sion was proteolysis significantly greater in ischemic
than in nonischemic myocardium. These results cannot be
attributed to the lack of insulin in the ischemic medium
because the hormone reduces cellular protein degradati on
(29) .
We also evaluated the effect of the medium itself on
proteolysis in control tissues obtained 2 hours after coro-
nary occlusion (Group I . Fig. 4) . Nonischemic myocardium
exhibited a lower (p < 0.05) rate of proteolysis in ischemic
than in aerobic medium , possibly as a result of hypoxia and
acidosis, or two conditions associated with depression in
intracellular protein degradation (18) . In contrast. proteol-
ysis in 2 hour ischemic myocardium did not differ signifi-
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dose-related fashion ( - 49% in low dose and -72% in high
dose, p < 0.001),
The effects of pepstatin and chymostatin on proteolysis
in ischemic myocardium are presented in Table 2. Treat-
ments were started 18 hours before sacrifice to allow max-
imal absorption of the inhibitors (21). Proteolysis in 3 hour
ischemic myocardium was not significantly different among
rats pretreated with pepstatin (16 mg/kg), chymostatin (120
mg/kg) or dimethylsulfoxide (8 mllkg). These results may
be due to a relative inability of pepstatin and chymostatin
to cross cell membranes (30-32) or to an inhibitory effect
of dimethylsulfoxide itself on myocardial proteolysis, or
both (see later).
The effects of combinations of antipain, leupeptin and
pepstatin, administered before coronary occlusion, on pro-
teolysis in ischemic myocardium are illustrated in Figure
5. Proteolysis in 15 minute ischemic myocardium was mark-
edly decreased (-65%, p < 0.001) by simultaneous pre-
treatment with antipain (20 mg/kg) and leupeptin (40 mg/
kg) and almost completely suppressed (- 88%, P < 0.001)
by the combination of antipain (20 mg/kg), leupeptin (40
mg/kg) and pepstatin (5 mg/kg). The latter combination
readministered 2 and 4 hours after coronary artery ligation
caused a prolonged inhibition of proteolysis, as demon-
strated by the effect observed in 6 hour ischemic myocar-
dium ( -72%, P < 0,05).
Effects of antipain, leupeptin, pepstatin and chymos-
tatin on proteolysis in nonischemic myocardium. The
effects of antipain and leupeptin on protein degradation in
nonischemic myocardium are summarized in Table 3. A
tendency toward decrease in proteolysis ( - 29%) was ob-
served in rats treated with antipain, but it did not achieve
statistical significance (p = 0.06). In contrast, leupeptin in
high dose markedly inhibited proteolysis ( - 54%, P < 0.02).
The combination of antipain, leupeptin and pepstatin de-
creased proteolysis by 43% (p < 0,05). This decrease was
not significantly different from that produced by leupeptin
alone.
The influence of pepstatin and chymostatin on protein
degradation in nonischemic myocardium is presented in Ta-
ble 2. When aerobic medium was used, no significant dif-
6-hour Ischemic
mvocardtum
(7)
(9)
, fi-rmmrteIschemic
myocardium
Nomschermc
myocardium
cantly in the two media, perhaps reflecting the fact that
severe ischemia-induced damage had rendered the proteo-
lytic machinery insensitive to variations of the environment.
Moreover, we compared nonischemic and ischemic tissues
incubated in the same media, thus eliminating differences
due to the medium itself. Figure 4 demonstrates that pro-
teolysis was not greater in ischemic than in nonischemic
myocardium even when the two tissues were incubated with
the same medium (either aerobic or ischemic),
Effects of antipain, leupeptin, pepstatin and chymos-
tatin on proteolysis in ischemic myocardium. The effects
of antipain (20 mg/kg), leupeptin in "low" dose (10 mg/
kg) and leupeptin in "high" dose (40 mg/kg), administered
10 minutes before coronary occlusion, on proteolysis in
ischemic myocardium 2 hours after occlusion are illustrated
in Figure 5, Antipain reduced the rate of protein breakdown
by 60% (p < 0,001). Leupeptin inhibited proteolysis in a
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Figure 2. Cumulative tyrosine release from slices as a function
of incubation time, Numbers in parentheses indicate the number
of rats studied at each time point Vertical bars indicate I standard
error of the mean,
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Figure 4. Effect of incubation medium on tyrosine release from
slices of nonischemic (white bars) and ischemic (dotted bars)
myocardium obtained 2 hours after coronary artery occlusion. Re-
sults are mean ± standard error of the mean. Numbers at the
bottom of each bar indicate the number of rats studied. *p <
0.05 versus nonischemic myocardium in aerobic medium.
ference was observed between rats receiving pepstatin (16
mg/kg, Group 18) and those receiving the vehicle dimeth-
ylsulfoxide (Group 17); however, dimethylsulfoxide itself
effected a marked inhibition of proteolysis (- 61 %, P <
0.01 compared with values in the rats injected with saline
solution, Group 16). It is possible that this effect of the
vebicle might have masked an action of pepstatin on myo-
carddl proteolysis. When ischemic medium was used, pro-
teolysis tended to be lower in pepstatin-treated rats (Group
II) than in control rats receiving dimethylsulfoxide (Group
10); however, the difference did not achieve statistical sig-
nificance. Chymostatin (120 mg/kg) did not produce any
appreciable effect on proteolysis.
o NONISCHEMIC MYOCARDIUM ~ 2hours
[ill] ISCHEMIC MYOCARDIUM ~ after occ lusion
Proteolysis in atria. Tyrosine release by atrial prepa-
rations incubated in aerobic medium was 1.57 :±: 0. 18 nmol/
mg protein per hour; release of tyrosine into the medium
was 0.15 ± 0 .01 nmol/mg tissue per hour.
Discussion
Modeling considerations. This investigation provides a
new model for studies of proteolysis during myocardial in-
farction. We measured the rate of protein breakdown in
nonischemic and ischemic rat myocardium by incubating
tissue slices in media supplemented with cycloheximide to
block protein synthesis (20) and by quantifying tissue release
of tyrosine. Because this amino acid is neither synthesized
nor metabolized by cardiac muscle (20) , its release in the
presence of cycloheximide reflects the degradation of tissue
proteins to amino acids (20,24). Most studies of cardiac
protein turnover during ischemia have used Langendorff
preparations (17, 18). Our model offers several advantages
over such preparations: it affords quantification of proteo-
lysis in regional acute myocardial ischemia produced in
vivo. and in specific regions (center of ischemic zone, non-
ischemic zone); furthermore. proteolysis can be assessed in
these regions even after the fi rst few hours of coronary
occlusion. This model, therefore, may be useful for inves-
tigations of regional myocardial metabolism during acute
infarction, especially if serial measurements over a pro-
longed period of time are needed.
The rationale for the selection of the incubation medium
was to determine the rate of proteolysis in each tissue under
conditions similar to those present in vivo. We therefore
incubated ischemic myocardium in ischemic medium(which
resembles extracellular fluid in conditions of acute flow
deprivation) and nonischemic myocardium in aerobic me-
dium (which resembles extracellular fluid of normally per-
fused tissues).
The validity of our measurements of proteolysis is COIl -
fi rmed by the datafro m atrial preparations . Tyrosine release
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Table 2. Effects of Dimethylsulfoxide, Pepstatin and Chymostatin on Proteolysis in Ischemic and Noruschemic Myocardium
Interventton
Control (DMSO. SOIl/kg)
DMSO, S OIl/kg plus
pcpstatin, 16 rng/kg
DMSO. S OIl/kg plus
chymostann, 120 rng/kg
Control (saline solution. S OI l/kg)
DMSO. S OI l/kg
DMSO, S ml/kg plus
pepstatin, 16 mg/kg
Control (DMSO, S OIl/kg)
DMSO, S OIl/kg plus
pepstatin. 16 mg/kg
DMSO, S OIl/kg plus
chymostatin, 120 mg/kg
Tyrosine Release (nm/mg protein per h)
A. 3 Hour Ischemic Myocardium
0.25 :!: 0.05
(n = 7 )
0.20 ::!: 006
(n = 6)
023 ::!: 0.04
(n = 6)
B Nomschemic Myocardium
No occlusion, aerobic medium
1.16 ::!: 0 IS
(n = 9)
0.45 ::!: 0 OS '
(n = 7)
0.43 ::!: 0.06
(n = 7)
3 Hours after occlusion, Ischemic medium
0 29 ::: 0.06
(n = 12)
0.13 ::!: 0.02
(n = 5 )
025 :!: 0.04
(n = 3)
Change From Control
- 20%
-S%
-61 %
-63%
-55%
-14%
*p < 0.01 versus saline solution; values are mean::!: standard error of the mean; DMSO = dimethylsulfoxide
by such preparations (1.57 ± 0.18 nmol/mg protein per
hour) was virtually identical to that reported by Curfman et
al. (20) (1.59 ± 0.16 nmol/mg protein per hour) in similar
conditions of incubation. Furthermore, release of tyrosine
into the medium (0.15 ± 0.01 nmol/mg tissue per hour)
was similar to that reported by Libby and Goldberg (30)
(0.33 ± 0.02 nmol/mg tissue per 2 hours).
Tissue slices were obtained with a Stadie-Riggs micro-
tome; minimal pressure was applied to the tissue to reduce
damage. Preliminaryexperiments showed that all slices ob-
tained with this technique were approximately0.5 mrn thick.
which allows diffusion of gases and soluble molecules to
and from the center of the section (33). To minimize tissue
damage, sections were made parallel to the epicardial sur-
face (that is, parallel to the orientation of the myocardial
fiber bands) and subepicardial slices were used. It has been
shown previously (34) that although the outermost layers
are damaged by mechanical trauma, most cells in sections
obtained by gentle slicing maintain near normal ultrastruc-
tural appearance as well as volume and ionic composition
of intracellular compartment.
In the present experiment. slices ofnonischemic ventricle
incubated in aerobi c medium (which contains insulin) re-
leased tyrosine at a rate of 0.122 ± 0.0 IS nmol/mg tissue
per hour. This value is reasonably close to that reported by
McKee et al. (35) (0.196 ± 0.010 nmol/mg tissue per hour)
in intact rat hearts perfused with insulin-free medium. The
difference between the two values may be accounted for by
the inhibition exerted by insulin on myocardial proteolysis
(29). The lower rates of proteolysis in our model may also
be due to the inability of the damaged outer layers of the
slice to maintain the high energy phosphate levels necessary
for intracellular proteolysis (36). However, this possibility
would lead to underestimation of the rate of proteolysis in
nonischemic myocardium but not in ischemic, energy-de-
picted tissue. Because our results indicate that proteinbreak-
down in ischemic myocardium is not greater than in non-
ischemic myocardium, underestimation of proteolysis in the
latter would strengthen our conclusions.
Proteolysis during the evolution of myocardial in-
farction. If either lysosomal or cytoplasmic proteinases were
activated early in the course of myocardial ischemia in suf-
fic ient quantity to precipitate substantial irreversible dam-
age, this increased enzyme activity might be manifested as
a generalized increase of myocardial proteolysis soon after
occlusion. Our data indicate that overall proteolysis does
not increase throughout the phase of acute myocardial is-
chemiaduring which irreversible cell damage develops (Fig.
3) . Thus, neither tissues studied very early in the devel-
opment of ischemic damage (15 minute ischemic myocar-
dium) nor those in which a more severe ischemic injury had
occurred (2 hour ischemic myocardium) exhibited higher
rates of proteolysis than nonischemic myocardium at cor-
responding times after occlusion. By 6 hours of occlusion,
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Table 3. Effects of Antipain, Leupeptin and Pcpstatin on Proteolysis in Nonischemic Myocardium
Intervention
Control I (saline solution, 0.25 ml)
Antipam, 20 rng/kg
Leupeptin, 40 rng/kg
Control II (saline solution, 1.2 ml)
Antipain, 20 mg/kg plus
lcupeptin, 40 mg/kg plus
pepstatin, 5 rng/kg
Tyrosine Release (nmol/mg protein per h)
A. No Occlusion
1.1 6 ± 0.14 (n = 14)
o82 ± 0.08t (n = 8)t
0.53 ± 0 07* (n = 5)
B. 15 Min After Occlusion
0.93 ± 0.14 (n = 6)
0.53 ± 0.11 t (n = 9)
Change From Control
- 29%
- 54%
-43%
* p < 0.001 versus control I; tp = 0.06 versus control I; tp < 0.05 versus control II. Values are mean ::t: standard error of the mean.
protein breakdown in ischemic myocardium actually de-
creased, At this time, irreversible damage has occurred in
almost all of the ischemic region (19). Even if it is assumed
that further damage occurs after 6 hours, our data obtained
at 18 and 24 hours indicate that such damage is not mediated
by an increase in cellular proteinase activity. No evidence
of increased proteolytic activity in ischemic tissues was
were incubated in the same medium (Fig. 4). These results
are consistent with those obtained previously in this labo-
ratory in a canine model of acute myocardial ischemia (37).
Failure of proteolysis to increase despite release of lyso-
somal cathepsins most likely results from the lack of energy
phosphates associated with ischemia. Indeed , an energy re-
quirement for intracellular proteolysis has been documented
in a variety of models (16,18,36).
Our study represents the first assessment of myocardial
proteolysis throughout the phase of acute myocardial in-
farction during which irreversible injury develops. Our
findings indicate that lysosomal and, more generally, cel-
lular proteinases do not undergo a generalized activation
during this phase, suggesting that proteolytic enzymes do
not contribute importantly to ischemic myocellular death.
However, failure of overall proteolysis to increase during
acutemyocardial infarction does notdisprove thehypothesis
that ischemia might selectively accelerate breakdown of vi-
tal cellular proteins while reducing degradation of other
components less crucial for immediate cell survival (16).
According to this hypothesis , unchanged levels of overall
proteolysis during ischemia may reflect the net balance be-
tween activation of key enzymes causing cell damage and
depression of other proteinases. Hence, without additional
evidence, the possibility that even baseline levels of pro-
teolysis may contribute to ischemic injury cannot be defin-
itively refuted.
Effects of proteinase inhibitors in ischemic myocar-
dium. This hypothesis could be tested by suppressing pro-
teolysis in acutely ischemic myocardium and by evaluating
the effect of such suppression on the extent of ischemic
damage. Therefore, in an attempt to determine whether such
an approach was feasible in the design of subsequent inves-
tigations, we studied the potential of proteinase inhibitors
to inhibit proteolysis in our model of acute myocardial
infarction .
Both leupeptinand antipain, administered in vivo before
coronary occlusion, produced a marked inhibition of pro-
teolysis in ischemic myocardium in the early phase of myo-
cardial infarction (Fig. 5). The combination of antipain and
leupeptin did not reduce protein breakdown any more than
did antipain alone (Fig. 5), suggesting that antipainexerted
its action by inhibiting leupeptin-sensitive enzymes (cath-
epsin B, calcium-activated neutral protease). Addition of
pepstatin to the combination of antipain and leupeptin re-
sulted ingreater inhibitionof proteolysis ( - 88versus - 65%).
Although the difference was not statistically significant, it
suggests an effect of pepstatin on protein breakdown of
ischemic tissues. The combination of antipain, leupeptin
and pepstatin readministered 2 and 4 hours after coronary
occlusion inhibited proteolysis even at 6 hours of ischemia
(Fig. 5). Thus, an almost complete suppression of protein
breakdown was produced by this combination in the isch-
emic region throughout the phase of myocardial infarction
during which irreversible damage develops.
These results represent the first successful attempt to
interfere with proteolysis in ischemic myocardium in vivo,
and have two important implications. First, they elucidate
the mechanisms of protein degradation during acute myo-
cardial infarction. Ourdata indicate that this process is largely
mediated by the enzymes sensitive to antipain, leupeptin
and pepstatin: lysosomal cathepsins A, B, D, L and H and
cytoplasmic calcium-activated neutral protease. Second, these
proteinase inhibitors appear to be a potentially useful tool
for assessing the significance of proteolysis in the genesis
of ischemic myocellular death.
Effects of proteinase inhibitors in nonischemic myo-
cardium. Unlike its effects in ischemic myocardium, an-
tipain did not decrease tyrosine release significantly in non-
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ischemic myocardium (Table 3). This difference may depend
on a greater permeability of the cell membrane of ischemic
myocytes to the inhibitor. Alternatively, the activity of an-
tipain-sensitive enzymes (cathepsins A and Band calcium-
activated neutral protease) might be enhanced during isch-
emia. A small decrease in total proteolysis (- 19%) has
been reported in cultured fetal mouse hearts exposed to
antipain (30 pM) for 2 days (31). Because proteolysis was
29% lower in antipain-treated than in control rats in the
present study and because this difference almost reached
statistical significance (p =:: 0.06), our data are not incon-
sistent with a minor effect of antipain on protein breakdown
in nonischemic myocardium.
Leupeptin (40 mg/kg) markedly inhibited proteolysis (Ta-
ble 3), an effect similar to that observed in ischemic myo-
cardium. These data provide the first demonstration of an
inhibition of myocardial proteolysis by in vivo administra-
tion of leupeptin, and confirm results obtained by other
investigators in different models (31,38). Because leupeptin
inhibits thiol-proteases (cathepsins B, Land Hand calcium-
activated neutral protease [21,22]), our results identify a
major role of this class of enzymes in normal cardiac protein
turnover.
Unlike the results found in ischemic tissues, the combi-
nation of antipain, leupeptin and pepstatin did not inhibit
proteolysis in nonischemic myocardium any more than did
leupeptin alone (Table 3). These data suggest that antipain
and leupeptin do not have additive effects in normal myo-
cardium and pepstatin, administered in vivo, does not in-
terfere with protein breakdown in this tissue. The latter
inference is substantiated by the failure of pepstatin (ad-
ministered starting 18 hours before sacrifice to allow max-
imal absorption [21]) to inhibit proteolysis in nonischemic
myocardium (Table 2). This result, which is consistent with
studies in other models (30,31,38), may reflect the relative
impermeability of normal sarcolemma to pepstatin (30-32).
Incubation of nonischemic myocardium in ischemic me-
dium, by reducing cell membrane integrity, might facilitate
entry of pepstatin into myocytes. We therefore administered
pepstatin starting 18 hours before sacrifice and measured
tyrosine release from slices of nonischemic ventricle incu-
bated in ischemic medium (Table 2). Proteolysis was 55%
lower in pepstatin-treated than in control rats. The difference
did not achieve statistical significance due to the scatter of
the data; nevertheless, this result suggests that an effect of
pepstatin on myocardial proteolysis may become manifest
in conditions of impaired cell membrane integrity.
Chyrnostatin did not affect proteolysis in nonischemic
myocardium (Table 2), possibly because of the poor perme-
ability of normal cell membranes to this compound (31).
We are grateful to Mary Slegowski for her techrucal assistance and to
Paula Parisius for performing protein determinanons
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